<DOC>
	<DOCNO>NCT01317797</DOCNO>
	<brief_summary>The purpose trial primarily investigate safety tolerability repeat subcutaneous injection MT203 patient mild moderate rheumatoid arthritis . Furthermore , amount MT203 blood measure investigated body respond MT203 treatment MT203 effective treatment rheumatoid arthritis .</brief_summary>
	<brief_title>A Trial Evaluate Safety Tolerability Namilumab ( MT203 ) Patients With Mild Moderate Rheumatoid Arthritis</brief_title>
	<detailed_description>The trial medication administer 2 dose level subcutaneous injection . Each patient receive three injection total . The trial duration consist screen period ( 28 - 2 day prior first injection ) treatment observation period ( 4 month ) . The trial require approximately 20 visit study site .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Outpatients active rheumatoid arthritis ( RA ) , accord ACR 1987 revise criterion , low moderate disease activity ( DAS28ESR ≥ 2.6 ≤ 5.1 ) 2 . Patients must stable dos methotrexate ( MTX ) ≥ 7.5 ≤ 25 mg/week least 12 week first injection , appropriate folic acid supplementation 3 . Age ≥ 18 year Screening 4 . Body weight least 50 kg Screening ; BMI : ≥ 18.0 ≤ 30.0 kg/m2 Screening 5 . Negative tuberculosis test Screening 6 . Heterosexually active male female patient childbearing potential oblige follow whatever contraceptive / breastfeed restriction may require concomitant medication ( ) , include methotrexate . In addition , heterosexually active male female patient childbearing potential require use effective doublemethod contraception ( one hormonal contraceptive intrauterine device one additional contraceptive method ) 1 month first administration IMP , course trial , 6 month last injection MT203 . No special requirement make female patient prove postmenopausal ( least 2 year last menstrual period FSH ≥ 40IU/L ) , surgically sterilize hysterectomized . Likewise special requirement heterosexually active male surgical sterilize . Pregnant lactate female patient exclude . 1 . Participation another clinical trial previous dose trial 2 . Use specified medication within certain timeframes use certain comedications 3 . History presence specify diseases 4 . Drug abuse 5 . Certain laboratory parameter outside specify range 6 . Donation blood 7 . Relevant decrease lung function 8 . Infections , frequent chronic infection , herpes zoster 9 . Females : positive pregnancy test 10 . Presence history tuberculosis 11 . History malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>MT203</keyword>
	<keyword>Human IgG1 monoclonal antibody</keyword>
	<keyword>GM-CSF monoclonal antibody</keyword>
</DOC>